Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Terminated 3Unknown 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 102Cyclophosphamide 74fludarabine 45Idarubicin 39Decitabine 36Etoposide 35Azacitidine 34Methotrexate 31Daunorubicin 30Vincristine 28Dexamethasone 27venetoclax 25Busulfan 24Imatinib Mesylate 23Radiotherapy 20Mercaptopurine 20Granulocyte Colony-Stimulating Factor 20Dasatinib 19Peripheral Blood Stem Cell Transplantation 18Mitoxantrone 17Doxorubicin 17Immunotherapy, Adoptive 16Rituximab 15Asparaginase 15Tretinoin 14Cladribine 14fludarabine phosphate 13Prednisone 13Prednisolone 13Melphalan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × IL32 protein, human × Other hematologic neoplasm × Clear all
NCT02809092 2019-10-15

Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

Hospital de Clinicas de Porto Alegre

Phase 1/2 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡